Core Viewpoint - Medtronic plc has announced the filing of a registration statement for an initial public offering (IPO) of its Diabetes business, which will operate under the name MiniMed, indicating a strategic separation from the parent company [1][2]. Company Overview - Medtronic plc is a leading global healthcare technology company headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries, focusing on innovative solutions for various health conditions [6]. - The company's mission is to alleviate pain, restore health, and extend life, with a diverse portfolio that includes cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems [6]. Diabetes Business - The Diabetes business at Medtronic aims to enhance diabetes management through advanced technology, including next-generation sensors and intelligent dosing systems, emphasizing customer experience [5]. - The separation of the Diabetes business is expected to be completed through capital markets transactions, with a preferred path being an IPO followed by a split-off [1][8]. IPO Details - MiniMed intends to list its common stock on the Nasdaq Global Select Market under the symbol MMED, although the number of shares and price range for the offering have not yet been determined [2]. - The IPO process will commence after the SEC review, subject to market conditions [2]. Underwriters - Goldman Sachs & Co. LLC, BofA Securities, Citigroup, and Morgan Stanley will serve as active bookrunners for the proposed offering, with additional support from several other financial institutions [4].